- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03926286
Fecal Microbial Transplant (FMT) for Sjogrens Syndrome
Fecal Microbial Transplant for Sjogrens Syndrome
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33133
- University of Miami
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Positive diagnosis of Sjogrens syndrome, defined by meeting two or more of the following three criteria:
- Positive serum anti-SS-A/Ro and/or anti-SS-B/La (or positive rheumatoid factor and ANA ≥ 1:320)
- Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus score ≥ focus/4 mm2
- Keratoconjunctivitis sicca with ocular staining score ≥ 3 (assuming that individual is not currently using daily eye drops for glaucoma, and has not had corneal surgery or cosmetic eyelid surgery in the last 5 years)
Or by both of the following:
Positive antibodies to one of the early markers of Sjogrens Syndrome:
- Anti-salivary gland protein 1 (SP1)
- Anti-carbonic anhydrase 6 (CA6)
- Parotid secretory protein (PSP) Ocular staining score ≥ 3
- Age ≥ 18 years at time of enrollment
- Able to provide signed and dated informed consent
- Women of child childbearing potential in sexual relationships with men must use an acceptable method of contraception§ from 30 days prior to enrollment until 4 weeks after completing study treatment.
Males must agree to avoid impregnation of women during and for four weeks after completing study treatment through use of an acceptable method of contraception*.
Includes, but is not limited to, barrier with additional spermicidal foam or jelly, intrauterine device, hormonal contraception (started at least 30 days prior to study enrollment), intercourse with men who underwent vasectomy.
- Includes, but is not limited to, barrier with additional spermicidal foam or jelly and vasectomy.
Participant exclusion criteria
Exclusion Criteria:
- Inability to provide informed consent and/or unable or unwilling to comply with protocol requirements.
- Antibiotics for at least 2 weeks prior to FMT.
- Active infection for >15 days: bacteremia, urinary tract infection, pneumonia or abdominal collection.
- Known or suspected toxic megacolon and/or known small bowel ileus.
- Previous FMT
- Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy.
- History of total colectomy or bariatric surgery.
- Antibiotics for the treatment of an active infection or anticipated antibiotic use during trial duration.
- Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy.
- Expected life expectancy < 6 months
- Patients with a history of severe anaphylactic or anaphylactoid food allergy.
- Solid organ transplant patients ≤ 90 days post-transplant or on active treatment for rejection.
- Neutropenia (<500 neutrophils/mL) or other severe immunosuppression. Patients on monoclonal antibodies to B and T cells, anti-tumor necrosis factor, glucocorticoids, antimetabolites, calcineurin inhibitors may be enrolled after consultation with their medical doctor.
- Renal failure (GFR <30 or dialysis)
- Human immunodeficiency virus+ controlled or not well controlled on antiretroviral therapy
- Regular probiotic supplement use within prior 2 weeks to enrollment
- Pregnancy or inability/unwillingness to use contraceptives.
- A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study.
- Exclusion on the discretion of the PI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FMT for Sjogrens
FMT- active ingredient coming from participant's screening stool
|
FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with reported adverse events (AEs) and serious adverse events (SAEs)
Time Frame: 7 months
|
As an evaluation of the safety of FMT, the number of participants with reported AEs and SAEs will be collected.
All occurrences of AEs and SAEs, regardless of relatedness to FMT, will be reported and assessed by the clinician using the NIH CTCAE.
|
7 months
|
Number of participants with stable microbiome engraftment
Time Frame: month 3
|
Engraftment will be analyzed via the Jensen-Shannon divergence (JSD).
The engraftment scores will be the ratio between the donors and recipients at the bacterial genus level.
Participants who successfully engraft will more closely resemble the donor microbial profile on JSD analysis.
|
month 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in dry eye symptoms
Time Frame: baseline, 1 week, 1 month, 3 months
|
Dry eye symptoms will be measured by the Ocular Surface Disease Index (OSDI) Scale 0-100 Continuous with higher scores representing greater dry eye symptoms
|
baseline, 1 week, 1 month, 3 months
|
Change in dry eye symptoms
Time Frame: baseline, 1 week, 1 month, 3 months
|
Dry eye symptoms will be measured by the Dry Eye Questionnaire 5 (DEQ5) Scale Range 0-22 Continuous with a higher number representing greater symptomatology of dry eye
|
baseline, 1 week, 1 month, 3 months
|
Change in diversity of bacterial communities
Time Frame: Pre FMT, 3 months post FMT
|
This will be captured via high-throughput 16S gene sequencing using DNA extracted from stool specimens in study participants.
The Shannon diversity index will be used as our primary measure of diversity.
|
Pre FMT, 3 months post FMT
|
Change in system immune profiles as measured by T cell populations
Time Frame: Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
System immune profiles will be evaluated by completing a comprehensive immuno-phenotypic profile from blood samples evaluating T cell populations including Th1, Th17, and T regulatory cells.
|
Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
Change in ocular and systemic symptoms as measured by the quality of life SF-12 Questionnaire
Time Frame: Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
Ranges 0-100 with higher scores representing a better quality of life
|
Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
Change in self-reported ocular pain as assessed by the Numerical Rating Scale(NRS)
Time Frame: Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
NRS Scoring Ranges from 0-10 with 0=no pain sensation and 10=the most intense eye pain imaginable
|
Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
Change in self-reported ocular pain as assessed by the Short-form McGill Pain Questionnaire(SFM-PQ)
Time Frame: Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
SFM-PQ Scoring Ranges from 0-45 with zero to 45 with a higher score indicating more server eye pain
|
Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
Change in self-reported ocular pain as assessed by the Neuropathic Pain Symptom Inventory (NPSI)
Time Frame: Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
NPSI Scoring Ranges from 0-100 with the higher score indicating the worse pain imaginable.
|
Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
Depression as assessed by the Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
PHQ-9 scoring Ranges from 0-27 with the higher score indicating a greater degree of depression
|
Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
Depression as assessed by the Symptom Checklist 90 for Depression (SCL-90 Depression)
Time Frame: Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
SCL-90 Depression scoring ranges from 0-4 with the higher score indicating a greater degree of depression.
|
Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
Anxiety as assessed by the Symptom Checklist 90 for Anxiety (SCL-90 Anxiety)
Time Frame: Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
SCL-90 Anxiety scoring ranges from 0-4 with the higher score indicating a greater degree of anxiety.
|
Pre-FMT, 1 Week, 1 Month, 3 months post FMT
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anat Galor, MD, MSPH, University of Miami
Publications and helpful links
General Publications
- De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019 Jan;195(1):74-85. doi: 10.1111/cei.13158.
- Zaheer M, Wang C, Bian F, Yu Z, Hernandez H, de Souza RG, Simmons KT, Schady D, Swennes AG, Pflugfelder SC, Britton RA, de Paiva CS. Protective role of commensal bacteria in Sjogren Syndrome. J Autoimmun. 2018 Sep;93:45-56. doi: 10.1016/j.jaut.2018.06.004. Epub 2018 Jun 20.
- Wang C, Zaheer M, Bian F, Quach D, Swennes AG, Britton RA, Pflugfelder SC, de Paiva CS. Sjogren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice. Int J Mol Sci. 2018 Feb 13;19(2):565. doi: 10.3390/ijms19020565.
- de Paiva CS, Jones DB, Stern ME, Bian F, Moore QL, Corbiere S, Streckfus CF, Hutchinson DS, Ajami NJ, Petrosino JF, Pflugfelder SC. Altered Mucosal Microbiome Diversity and Disease Severity in Sjogren Syndrome. Sci Rep. 2016 Apr 18;6:23561. doi: 10.1038/srep23561.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Sjogren's Syndrome
Other Study ID Numbers
- 20170733
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sjogren's Syndrome
-
The Cleveland ClinicBristol-Myers SquibbWithdrawnRheumatoid Arthritis | Inflammatory Arthritis | Primary Sjogren's Syndrome | Secondary Sjogren's SyndromeUnited States
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
Stanford UniversityWithdrawnPrimary Sjogren's Syndrome
-
Matthew C. BakerWithdrawnPrimary Sjogren's SyndromeUnited States
-
University College, LondonCambridge University Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals... and other collaboratorsActive, not recruitingSjogren's Syndrome Childhood-onsetUnited Kingdom, Ireland
-
Keio UniversityUnknown
-
Parion SciencesCompletedXerostomia | Dry Mouth Associated With Sjogren's SyndromeUnited States
-
University Hospital MuensterNovartisCompletedPrimary Sjogren's SyndromeGermany
-
Akdeniz UniversityCompleted
Clinical Trials on FMP-30
-
University of Colorado, DenverOpenBiomeWithdrawnSevere Motility Disorder
-
University of EdinburghAccord Clinical ResearchNot yet recruitingSystemic Lupus Erythematosus
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; United States Agency for International Development (USAID); The...Completed
-
Microbiome Health Research InstituteBoston Medical CenterCompletedAntibiotic Resistant StrainUnited States
-
Mayo ClinicCompleted
-
Chang Gung Memorial HospitalCompleted
-
National Yang Ming UniversityCompletedTranscranial Magnetic Stimulation | Non-specific Chronic Neck Pain | Neuromuscular Control | Office WorkersTaiwan
-
University of Texas at AustinCompleted
-
Rush University Medical CenterWithdrawnChronic Low-back Pain | Peripheral Neuropathy | CRPS
-
University Malaysia SarawakUniversity of MalayaCompleted